Literature DB >> 1779410

In vivo testing of a biostable polyurethane.

M Szycher1, A M Reed, A A Siciliano.   

Abstract

At present all the commercially available "medical grade" urethane elastomers exhibit a phenomenon known as environmental stress cracking (ESC). This phenomenon is characterized by surface microcracking when the elastomer is elongated while in vivo. The degree of strain that is required to initiate microcracking varies from composition to composition. It has been found that harder compounds generally tend to have a higher strain threshold than corresponding softer ones. We theorized that this degradation occurs when certain enzymes (present only in vivo) attack and break down the ether linkages that link the polymer molecules together. Those elastomers that contain more ether linkages (such as the softer compositions) appear to microcrack more easily than elastomers with fewer ether linkages (such as the harder ones). The molecular composition of ChronoFlex urethane has been chosen so that the finished elastomer will be free of ether linkages; thus, it is expected to be immune from environmental stress cracking.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1779410     DOI: 10.1177/088532829100600202

Source DB:  PubMed          Journal:  J Biomater Appl        ISSN: 0885-3282            Impact factor:   2.646


  3 in total

1.  Development of thin elastomeric composite membranes for biomedical applications.

Authors:  S H Teoh; Z G Tang; S Ramakrishna
Journal:  J Mater Sci Mater Med       Date:  1999-06       Impact factor: 3.896

2.  End-point immobilization of heparin on plasma-treated surface of electrospun polycarbonate-urethane vascular graft.

Authors:  Xuefeng Qiu; Benjamin Li-Ping Lee; Xinghai Ning; Niren Murthy; Nianguo Dong; Song Li
Journal:  Acta Biomater       Date:  2017-01-06       Impact factor: 8.947

3.  A Novel Resorbable Composite Material Containing Poly(ester-co-urethane) and Precipitated Calcium Carbonate Spherulites for Bone Augmentation-Development and Preclinical Pilot Trials.

Authors:  Claudia Rode; Ralf Wyrwa; Juergen Weisser; Matthias Schnabelrauch; Marijan Vučak; Stefanie Grom; Frank Reinauer; Adrian Stetter; Karl Andreas Schlegel; Rainer Lutz
Journal:  Molecules       Date:  2020-12-28       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.